Hot Topics in Pediatric Infectious Diseases - Duke Pediatrics Intranet
Hot Topics in Pediatric Infectious Diseases - Duke Pediatrics Intranet
Hot Topics in Pediatric Infectious Diseases - Duke Pediatrics Intranet
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
The real truth…• They never give you a denom<strong>in</strong>ator to theirpercentages– They sampled macrolide resistant clones (20% of total)and 20% of those were MDR• 20% of 20% is 4% of the total! Worrisome yes, but does notmean we should panic!• The study was funded by Sanofi-Aventis, makersof Ketek (telithromyc<strong>in</strong>)– At the time, the company wanted to cont<strong>in</strong>ue with pediatric developmenteven though their drug was <strong>in</strong>vestigated because of severe liver toxicity(deaths and FHF requir<strong>in</strong>g transplant <strong>in</strong> 5 patients!)– The FDA, after much embarrassment, withdrew approval <strong>in</strong>Feb07
Change language